Abstract: Leading European cardiologists describe the current and planned future management for acute ST elevation myocardial infarction in their hospitals and countries in 80 to 100 words.
A revolution in the management of acute ST elevation myocardial infarction (STEMI) over the past decade has transformed the emergency and cardiological services for acute STEMI patients. Underpinning this revolution has been increasing evidence demonstrating the benefits of primary percutaneous coronary intervention (PCI) and pre-PCI and post-PCI management on acute STEMI mortality and morbidity rates. Within-country and intercountry initiatives are now in place or in development throughout Europe to aid this revolution in line with national and European guidelines.
In this article, leading European cardiologists describe in 80 to 100 words what has been achieved so far in their hospitals and countries: the current management for STEMI, including acute and long-term care, rehabilitation, types of stents and drugs used, and how these will improve in the near future. The result is a fascinating glimpse of the work that has been done and is in progress throughout Europe to transform the cardiological services and outcome for patients who have acute STEMI. Steen Dalby Kristensen, MD, DMSc, FESC, professor of cardiology, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark "The 4 STEMI centres in Denmark are located in Copenhagen, Odense, Aarhus, and Aalborg, and they offer a 24-hour, 7 days a week primary PCI service for all patients with acute STEMI. The diagnosis is usually established in the ambulance to direct the patient straight to the cath lab. Thrombolysis is not used. Standard medical therapy in the ambulance is aspirin, a P2Y 12 inhibitor, and unfractionated heparin. Most patients are treated with thrombus aspiration and direct stenting with a drug-eluting stent and are usually observed in the STEMI centre for 12 to 48 hours before transferral to their local hospital for rehabilitation. Patients are usually included in research projects on new devices and drugs. Reduction of patient and system delay by public campaigns and educational programmes is a focus area." (population ≈320, 000, area ≈103, 000km 2 ) Karl Andersen, MD, PhD, FESC, professor of cardiology, Landspitalinn, University Hospital of Iceland, IS-101 Reykjavik, Iceland "During the past 25 years, the incidence and mortality rates of STEMI have dropped by 80% in Iceland, mostly due to improvements in population risk factor levels. The University Hospital of Iceland, Landspitalinn, has a catchment area of 90% of the Icelandic population and is the only interventional centre in the country. A 24-hour PCI service was established in 2004. Currently, 94% of all STEMI patients receiving reperfusion therapy are treated with acute PCI. More than 95% of all STEMI patients receive a stent, and ≈30% receive drugeluting stents. The median door-to-balloon time is 48 minutes, and the 30-day mortality rate after STEMI in Iceland is 6.5%. The main emphasis in STEMI treatment is to further shorten prehospital delays and optimise medical treatment according to international guidelines." Ireland (population ≈4.5 million, area ≈70, 000km 2 ) David P. Foley, MD, PhD, FRCPI, FESC, FACC, interventional cardiologist, professor of cardiology, Beaumont Hospital, Dublin, Republic of Ireland; chair, Irish Cardiac Intervention Society "In the Republic of Ireland, primary PCI for STEMI has been carried out on a variable ad hoc basis for many years. Penetration increased to ≈75% of presenters in urban areas in 2011, who were treated at 9 centres nationwide. In a typical case, transradial access has increased dramatically, glycoprotein IIb/IIIa antagonist use is highly likely, and thrombus aspiration is routine, as is drug eluting stent implantation. Intravascular ultrasound and optical coherence tomography are used with increasing frequency, depending on the operator. A strategy of culprit lesion-only PCI is usual, with deferred PCI for bystander lesions. Patients transported from district hospitals are mostly directly repatriated unless intubated or needing intra-aortic balloon pump. A national protocol for reperfusion therapy to provide access to primary PCI for all patients nationwide starts in October 2011: ≈85% of the population live within 90 minutes of a PCI centre, and those with STEMI will be ambulanced directly to the nearest of 4 designated 24/7 PCI centres with full capability. Emergency medical technicians obtain electrocardiograms in the ambulance, and after confirmation by the receiving cardiology team, administer aspirin, clopidogrel, and low molecular weight heparin loading doses en route. Patients with STEMI and >2 hours from a PCI centre receive a thrombolytic locally and are transferred to the closest PCI centre in case they need rescue PCI. Prospective data collection on all aspects of the programme will be assessed to ensure optimal outcomes according to international best practice. Hospital stay is 2 to 3 days for uncomplicated cases. Cardiac rehabilitation is offered to all patients." . According to the Latvian registry of acute coronary syndromes, the reperfusion rate for STEMI patients increased from 56% in 2005 to 81% in 2010, mainly due to an increase in primary PCI from 14% in 2005 to 65% in 2010. Drug-eluting stents were used in ≈50% of patients. Adherence to dual antiplatelet therapy, glycoprotein IIb/IIIa inhibitors, lowmolecular-weight heparin, and statins has dramatically improved. Consequently, the intrahospital mortality rate has decreased by 34% across the country. The challenges over the next 10 years are to further increase the use of drug-eluting stents and total reperfusion rates and to provide primary PCI for 90% to 100% of STEMI patients.
Iceland

orway (population ≈5 million, area ≈325, 000km 2 )
Karel Kier-Jan Kuiper, MD, PhD, invasive cardiologist, Department of Heart Disease, Haukeland University Hospital, -5021 Bergen, orway "Primary PCI for STEMI is provided 24/7 in 7 regional PCI centres throughout Norway. At our hospital covering West Norway with an aeromedical service, primary PCI is performed for 90% of STEMI patients. Ambulance-transmitted electrocardiograms are evaluated for STEMI at the nearest hospital, and dual antiplatelet therapy is started before transport to a PCI centre. Thrombus aspiration and second-generation drug-eluting stents are increasingly used. For patients with a transfer time >90 to 120 minutes, thrombolysis is administered locally, followed by early angiography and ischaemia-driven revascularisation. Care after discharge comprises dual antiplatelet therapy, statins, β-blocker, and an offer for rehabilitation. Improvements will focus on reducing 'time to treatment' for patients who have a long transfer time to a PCI centre." "The past decade has seen a transformation in the management of STEMI in the United Kingdom. From a country where thrombolytic treatment was the standard of care, the development of integrated networks of prehospital care for acute STEMI and the implementation of primary PCI as the dominant treatment has revolutionised management and outcomes. Telemetry of the electrocardiogram to the cardiac centre is increasingly employed, and bypassing of hospitals without primary PCI facilities has expedited treatment. Now, 88% of patients receive primary PCI within 90 minutes of hospital presentation, according to the Myocardial Ischaemia National Audit Project Public Report 2010, and both 30-day and mortality rates for all patients (median age 74 years) fell from 12.35% in 2003 to 8.4% in 2010, with corresponding declines in 6-month mortality rates. However, there remains scope for further improvement, including the challenge of late presentation in older and more frail patients." Thrombolysis was abandoned in our hospital in 1995. The situation evolved similarly in the entire country over the next 7 years. Thrombolysis is rarely (<1%) used. Twentytwo primary PCI centres cover our 10.5 million population, with each centre performing 200 to 450 primary PCIs for STEMI each year. STEMI management in the acute phase includes prehospital electrocardiographic diagnosis and antithrombotic medication (usually aspirin, clopidogrel, and heparin) and direct transport to the nearest tertiary primary PCI centre for emergency coronary angiography followed by primary PCI. Uncomplicated patients are discharged after ≈3 to 4 days. Bare metal stents have been used most often, but this is changing with the introduction of newgeneration drug-eluting stents. Long-term care includes preventive measures, rehabilitation (outpatient or in specialised rehabilitation centres), and medication (aspirin, clopidogrel, β-blockers, statins, angiotensin-converting enzyme inhibitors). Improvements in the near future will include the wider use of new-generation drug-eluting stents and the replacement of clopidogrel by more potent antiplatelet agents (ie, prasugrel or ticagrelor)." Germany (population ≈81 million, area ≈360,000km 2 ) Thomas Münzel, MD, professor and chief of cardiology, Johannes Gutenberg University, Mainz, Germany "The prognosis for STEMI has considerably improved in Germany over the past 20 years, primarily due to the network of cath labs allowing rapid access to primary PCI. We put much emphasis on decreasing the time delay to reperfusion. Most delay is caused by the patients themselves, so in Mainz, we have started awareness campaigns emphasising what patients with chest pain should do. We also perform a structured diagnosis, risk stratification, and treatment of all patients with an acute coronary syndrome in chest pain units. A network of certified chest pain units is being established throughout Germany and so far 130 have been certified within a couple of years by the German Cardiac Society."
The etherlands (population ≈17 million, area ≈34, 000km 2 ) Jan J. Piek, MD, PhD, FESC, FACC, FAHA, professor of clinical cardiology and director, Heart Centre, Academic Medical Centre, Amsterdam, the etherlands "Completion of the randomised Zwolle trial almost 20 years ago, showing the superiority of primary PCI in the treatment of acute myocardial infarction, 1 led to a gradual acceptance in other Dutch regions to use primary PCI as the first line of treatment. Now almost all patients with acute myocardial infarction are treated with primary PCI. The wellequipped ambulance system, short call-to-needle times, and high-volume centres have contributed to its success, resulting in a gradual decline in the mortality rate, which is among the lowest in the world. This achievement has not led to a laidback attitude, but has rather stimulated Dutch interventionalists to conduct numerous randomised trials to evaluate adjuvant therapy in primary PCI varying from thrombosuction devices, glucose metabolism modulation, drug-eluting stents, and IIb/IIIa receptor blockers to cell therapy. Therefore, if you are in the unfortunate situation to experience your first acute myocardial infarction, the Netherlands is a good place to be." Plus has documented the diagnostic and therapeutic measures for acute myocardial infarction, with most hospitals participating. STEMI management is within the guideline-recommended timeframe (>80% undergo PCI, >75% within <90 minutes), 25% received bare metal stents, 70% received drug-eluting stents, ≈90% received the recommended immediate and discharge drugs, and ≈54% attended in-or outpatient rehabilitation. Efforts continue to maintain this high-quality management and to further shorten delays using prehospital diagnostics and immediate transportation of STEMI patients to a PCI centre. Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC, professor of internal medicine and director, University Hospital Centre Zagreb Salata 2, 10 000 Zagreb, Croatia "In Croatia, a network was established a number of years ago based on geographical areas and fast transport to the nearest hospital. A helicopter service is used for transportation from the islands and more remote areas, and ambulances, mostly physician-manned, are used in other parts of the country. In the hospitals in this network, primary PCI is performed in STEMI patients. Bare metal stents are usually used rather than drug eluting stents (≈5% of patients) for financial reasons. Coronary artery bypass grafting is performed if needed. Aspiration thrombectomy is used routinely in my hospital.
"A relatively high percentage of post-STEMI patients receive rehabilitation in specialised centres. European Society of Cardiology guidelines are strictly followed for drug therapy. Improvements are always possible, particularly in further development of the organisation, especially to shorten the door-to-balloon time. by primary PCI, but at nights and on weekends and in hospitals without invasive facilities, thrombolysis is the mainstay of treatment. The low rates of primary PCI are due to a lack of trained interventionalists. We are addressing this with intensive training programmes to provide enough trained personnel for a 24-hour 7 days a week primary PCI programme by 2012. Whether this happens, however, depends on whether the government will provide funding in this time of public cost cutting.
"Stents are used in almost 100% of primary PCIs. Until recently, mainly due to concerns about thrombosis with drug-eluting stents, the majority were bare metal stents. This has changed, and >80% of stents for primary PCI are now drug-eluting stents. All guideline drugs are in use with a few exceptions: clopidogrel is the thienopyridine in general use, and although prasugrel is available, it is not in use in the state hospitals due to its cost. Bivalirudin is not widely available. All patients are followed up by a cardiologist with guideline-based management in both state and private centres: 80% of the population is eligible for free healthcare.
"No large-scale official rehabilitation programmes have been available. We are addressing this, partly by the establishment this year of a new working group on cardiac rehabilitation to study this issue and make recommendations." Greece (population ≈11.5 million, area ≈132,000km 2 ) Gerasimos Filippatos, MD, FACC, FCCP, FESC, chief of the Heart Failure Unit, Department of Cardiology, Athens University Hospital, Athens, Greece "In Greece, with thousands of islands and only 10 primary PCI centres, the reperfusion rates for STEMI in 2005 were ≈65%. Of the patients admitted to hospitals with a cath lab, 24% had primary PCI in comparison with 1% of patients admitted to small peripheral hospitals. An unexpected finding is the relative underuse of common treatments in the peripheral hospitals. Initiation of STEMI networks in most regions, coordinated centrally by Professor John Nanas, has improved reperfusion rates and the use of primary PCI and evidence-based therapies." Reperfusion was by primary PCI in 94%, thrombolysis in 4%, and urgent coronary artery bypass grafting in 1%. During primary PCI, ≈57% of patients were treated with IIb-IIIa antagonists, ≈6% with bivalirudin, and ≈46% with an aspiration/protective device. Stents were implanted in 90% of patients (bare metal 78%, drug-eluting 18%, both types 3.4%). Medical treatment on discharge usually includes aspirin, clopidogrel, statin, β-blocker, and angiotensin-converting
